• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Graybug Vision launches trial for injectable, depot formulation of wet AMD drug

September 20, 2017 By Sarah Faulkner

Graybug VisionGraybug Vision said yesterday that it launched the first clinical trial of its lead product, GB-102, in patients with wet age-related macular degeneration.

The two-part study is slated to evaluate patients being treated with available intravitreal anti-VEGF agents who are later switched over to just GB-102. The first part of the study will evaluate up to four dose levels of GB-102. Researchers plan to follow patients with monthly evaluation, assessing safety, tolerability, visual acuity and optical coherence tomography of the retina, for 8 months.

The second part of the study is designed to evaluate the safety and efficacy of repeated intravitreal injections of two dose levels of GB-102 compared to a standard intravitreal regimen of aflibercept (Eylea).

Graybug Vision’s lead product is a intravitreal injectable depot formulation of a tyrosine kinase inhibitor, sunitinib malate, that blocks multiple angiogenesis pathways, the company said. The novel formulation could potentially be administered just twice per year, Graybug Vision touted, according to preclinical studies.

“Wet AMD is a leading cause of irreversible vision loss in older adults and current treatments are extremely burdensome due to the need for frequent visits to the retinal specialist for IVT injections,” CMO Dr. Charles Semba said in prepared remarks. “We believe GB-102 has the potential for twice-yearly treatment and may provide the opportunity to dramatically change the standard-of-care by reducing the frequency of injections for patients and the treating physician.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: graybugvision

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS